

Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis

NCT04869436

Status	RECRUITING
Phase	Phase 4
Sponsor	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Enrollment	27 participants

Key Eligibility Criteria

Inclusion (4)

- Patients older than 18 years old
- Chronic rhinosinusitis with Nasal Polyps
- Olfactory loss
- Clinical indication for treatment with Dupilumab

Exclusion (7)

- Patients with olfactory loss from other causes such as:
- Sinonasal malignancies
- Trauma
- Idiopathic olfactory loss
- Use of cocaine
- ... and 2 more (see full listing online)

Locations (1 total)

St. Joseph's Health Care, London, Ontario, Canada